Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Start low, go slow, but don't go this way yet.

× No keyword cloud information.

28 in total

Review 1. Use of laboratory testing to guide 6-mercaptopurine/azathioprine therapy.

Authors: Gary R Lichtenstein
Journal: Gastroenterology Date: 2004-11 Impact factor: 22.682

2. Toxicity of 6-thioguanine: no hepatotoxicity in a series of IBD patients treated with long-term, low dose 6-thioguanine. Some evidence for dose or metabolite level dependent effects?

Authors: L P L Gilissen; L J J Derijks; A Driessen; L P Bos; P M Hooymans; R W Stockbrügger; L G J B Engels
Journal: Dig Liver Dis Date: 2006-12-26 Impact factor: 4.088

3. Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease.

Authors: J Belaiche; J P Desager; Y Horsmans; E Louis
Journal: Scand J Gastroenterol Date: 2001-01 Impact factor: 2.423

4. On tolerability and safety of a maintenance treatment with 6-thioguanine in azathioprine or 6-mercaptopurine intolerant IBD patients.

Authors: Nanne-K-H de Boer; Luc-J-J Derijks; Lennard-P-L Gilissen; Daniel-W Hommes; Leopold-G-J-B Engels; Sybrand-Y de-Boer; Gijsbertus den Hartog; Piet-M Hooymans; Anja-B-U Mäkelburg; Barend-D Westerveld; Anton-H-J Naber; Chris-J-J Mulder; Dirk-J de Jong
Journal: World J Gastroenterol Date: 2005-09-21 Impact factor: 5.742

5. The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease.

Authors: Benjamin A Goldenberg; Patricia Rawsthorne; Charles N Bernstein
Journal: Am J Gastroenterol Date: 2004-09 Impact factor: 10.864

6. Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease.

Authors: Carmen Cuffari; Themistocles Dassopoulos; Lisa Turnbough; Richard E Thompson; Theodore M Bayless
Journal: Clin Gastroenterol Hepatol Date: 2004-05 Impact factor: 11.382

7. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease.

Authors: J Winter; A Walker; D Shapiro; D Gaffney; R J Spooner; P R Mills
Journal: Aliment Pharmacol Ther Date: 2004-09-15 Impact factor: 8.171

Review 8. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety.

Authors: Marla C Dubinsky
Journal: Clin Gastroenterol Hepatol Date: 2004-09 Impact factor: 11.382

9. Individualizing therapy with 6-mercaptopurine and 6-thioguanine related to the thiopurine methyltransferase genetic polymorphism.

Authors: L Lennard; J S Lilleyman
Journal: Ther Drug Monit Date: 1996-08 Impact factor: 3.681

10. 6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment.

Authors: Luc J J Derijks; Dirk J de Jong; Lennard P L Gilissen; Leopold G J B Engels; Piet M Hooymans; Jan B M J Jansen; Chris J J Mulder
Journal: Eur J Gastroenterol Hepatol Date: 2003-01 Impact factor: 2.566